Trastuzumab deruxtecan benefit for some advanced gastric cancers

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer

Abemaciclib potential therapeutic option for Kaposi sarcoma

Making immune check point inhibitors for lung cancer cost-effective in LMICs

ASCO 2025: Latest in EGFR positive NSCLC

Ecological evaluation of climate risks for cancer survivors

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

Sacituzumab govitecan helps postpone progression in some PD-L1-positive triple-negative breast cancer patients

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Characteristics associated with longer-term OS with NALIRIFOX regimen in metastatic pancreatic adenocarcinoma